was released by the rating agency) FRANKFURT/LONDON, July 28 (Fitch) Fitch Ratings has assigned Investitionsbank Berlin ( IBB ) a Long-term Issuer Default Rating (IDR) of 'AAA', Short-term IDR of 'F1+', Support Rating of '1' and Support
By Left Banker : Since my recent retirement, I have been focusing research efforts on refining my retirement income account. Thus in my recent writings on Seeking Alpha I have emphasized retirement income strategies. In addition to that income account, I also maintain a growth portfolio. Here, I ...
When the world’s top central banker speaks, markets pay very close attention. Last week, Federal Reserve Chair Janet Yellen was on Capitol Hill delivering her semi-annual testimony on monetary policy. And in her remarks she stuck mostly to the script signaling that a high degree of monetary policy
larger players in the sector by buying ETFs, such as the SPDR S&P Biotech ETF (NY XBI ) and the iShares Nasdaq Biotechnology (NASDAQ: IBB ) with our preference being the SPDR S&P Biotech due to it having less exposure to the more speculative
for covered recipients. Predictably, medical industry observers are confident that the disclosures will generate substantial interest from a wide swath of the health care sector. ETFs: IBB , BIB , IRY , IXJ , BIS , DRGS Post your comment!
Biotech shares retreat today as the group continues its downtrend that started on July 7. Shares of ( IBB -1.8% ) are down ~5% from July 3's peak of $266.43. Contributing to the sell-off is the Federal Reserve's Monetary
remain little-changed. Small caps ( IWM -0.7% ) and momentum sectors like social media ( SOCL -1.1% ) and biotech ( IBB -1.1% ) are selling off as the Fed boss says their valuations "appear to be stretched." The Q&A is underway; live blog
mortality rate is as high as 90%. It is spread by close contact with the body fluids and tissues of infected people. There is no treatment or vaccine available. ETFs: BBRC , EMBB ETFs: IBB , BIB , IRY , IXJ , BIS , DRGS Post your comment!
portfolio. This one illustrates the pros and cons of tactical allocation with a former holding: the iShares Nasdaq Biotechnology ETF ( IBB ). It is just an example; however, this trade is quite typical of the pros and cons of tactical allocation
Bloomberg reports that privately-held Omega Pharma N.V. is exploring a sale of the company for as much as $4B. The Belgian firm was taken private ~three years ago by the founder. ETFs: IBB , BIB , IRY , IXJ , BIS , EWK , DRGS Post your comment!